Senores Pharmaceuticals IPO Allotment Out: GMP At 61.38%, A Step-By-Step Guide To Check Allotment Status Online

Senores Pharmaceuticals IPO Allotment Status: The allotment of the Senores Pharmaceuticals IPO has been finalised. The initial public offering of Senores Pharmaceuticals Ltd closed on Tuesday and received an overall 97.86 times subscription. The Senores Pharmaceuticals IPO listing will take place on Monday, December 30. The latest GMP currently stands at 61.38 per cent, signalling a robust listing.

The initial public offering of Senores Pharmaceuticals Ltd, which was opened on between December 20 and December 24, received an overall 97.86 times subscription. The retail category recieved a 93.16 times subscription in total, the NII (non-institutional investors) portion got 100.35 times subscription. Its QIB (qualified institutional buyer) category has been subscribed by 97.84 times.

The price band of the IPO was fixed at Rs 372 to Rs 391 apiece.

The shares of Senores Pharmaceuticals Ltd are scheduled to be listed on both BSE and NSE on December 30, Monday.

The IPO allotment has been finalised in the Thursday evening. Investors who have been allotted the IPO received a bank debit message. Investors can also check the IPO allotment status on the websites of BSE and NSE, as well as on registrar Link Intime’s portal.

currently trading at Rs 631 per share in the grey market, which is Rs 240 or 61.38 per cent higher than the IPO issue price of Rs 391. It indicates a stellar listing on December 30.

The GMP is based on market sentiments and keeps changing. ‘Grey market premium’ indicates investors’ readiness to pay more than the issue price.

Senores Pharmaceuticals IPO: How To Check Allotment Status Online?

The IPO allotment status can be checked online by following these steps:

1) Go to the official BSE website via the URL —https://www.bseindia.com/investors/appli_check.aspx.

2) Under ‘Issue Type’, select ‘Equity’.

3) Under ‘Issue Name’, select ‘Senores Pharmaceuticals Ltd’ in the dropbox.

4) Enter your application number, or the Permanent Account Number (PAN).

5) Then, click on the ‘I am not a robot’ to verify yourself and hit ‘Search’ option.

Your share application status will appear on your screen.

You can also visit direct Link Intime Ltd’s portal — https://www.linkintime.co.in/Initial_Offer/public-issues.html and check the Senores Pharmaceuticals IPO allotment status.

Senores Pharmaceuticals IPO: More Details

The Ahmedabad-based company’s IPO is a combination of fresh issuance of shares worth Rs 500 crore and an offer-for-sale (OFS) of up to 21 lakh shares valued Rs 82.11 crore, by promoters and other selling shareholders, at the upper-end of the price band.

Senores Pharmaceuticals Ltd has secured nearly Rs 261 crore from anchor investors.

Proceeds from the fresh issue will be utilised for setting up a manufacturing facility for production of sterile injections in its Atlanta facility; funding the working capital requirements of the company and its subsidiaries, supporting inorganic growth through acquisition and other strategic initiatives and payment of debt. Besides, a portion will be used for general corporate purposes.

Senores Pharmaceuticals specialises in identifying, developing, and manufacturing a wide array of specialty, underserved, and complex pharmaceutical products, positioning itself as a preferred partner for select customers.

The company has several products in major therapeutic segments, including antibiotics, anti-bacterial, anti-fungal, and blood lines.

As of March 2024, the company had three R&D facilities in India and the US and is in the process of consolidating R&D facilities into one proposed dedicated facility in Ahmedabad.

Related Posts

CCRAS committee reviews research programmes and future initiatives to strengthen Ayurveda research

The 106th meeting of the Internal Finance Committee (IFC) of the Central Council for Research in Ayurvedic Sciences (CCRAS) was held at the Regional Ayurveda Research Institute (RARI), Itanagar. The…

Maharashtra FDA increases medicine and cosmetics testing, flags 108 samples as non-compliant

Maharashtra’s Food and Drug Administration (FDA) has significantly increased laboratory testing of medicines and cosmetics, with 3,020 samples collected and 2,112 examined between June and August 2026. Of the drug…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

CCRAS committee reviews research programmes and future initiatives to strengthen Ayurveda research

CCRAS committee reviews research programmes and future initiatives to strengthen Ayurveda research

Maharashtra FDA increases medicine and cosmetics testing, flags 108 samples as non-compliant

Maharashtra FDA increases medicine and cosmetics testing, flags 108 samples as non-compliant

Assam: Drug inspector couple dismissed from service over bribery, disproportionate assets cases

Assam: Drug inspector couple dismissed from service over bribery, disproportionate assets cases

Health ministry strengthens allied and healthcare education and professional standards

Health ministry strengthens allied and healthcare education and professional standards

Siddhanta Super Speciality Hospital’s registration, licence cancelled in Bhopal: CMHO inspection finds 19 serious lapses from emergency to ICU; dialysis rules violated

Siddhanta Super Speciality Hospital’s registration, licence cancelled in Bhopal: CMHO inspection finds 19 serious lapses from emergency to ICU; dialysis rules violated

Chemist selling narcotics held, medical store sealed

Chemist selling narcotics held, medical store sealed